Literature DB >> 18698128

Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench.

Matthew R Allen1.   

Abstract

Osteonecrosis of the jaw (ONJ) has received significant attention as a potential side effect of bisphosphonate treatment. The limited understanding of the underlying pathophysiology of the condition emphasizes the need to transition ONJ research from the bedside to the bench, supplementing ongoing clinical research with animal/basic science studies. The goal of this review is to briefly highlight the most commonly proposed mechanisms for ONJ and then summarize our laboratory's recent efforts to begin transitioning ONJ research to an animal model. Remodeling suppression, disrupted angiogenesis and infection have all been proposed to connect bisphosphonates to ONJ, although most supportive data for each of these are either indirect or nonexistent. Our laboratory has begun studying the dog as a potential model of ONJ. We have shown regions of necrotic bone matrix within the mandible of dogs treated with oral or intravenous bisphosphonate. We hypothesize these regions are the result of remodeling suppression, and if combined with additional factors such as dental intervention or infection, would result in manifestation of exposed oral lesions, the clinical definition of ONJ. Although these findings suggest the dog may be a viable animal model to study ONJ, many questions remain unanswered. No matter what animal model is found to mimic the clinical presentation of ONJ, once established it will allow significant progress toward understanding the specific role of bisphosphonates in the pathophysiology of ONJ and if/how the entity of ONJ can best be treated and prevented. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18698128      PMCID: PMC2824205          DOI: 10.1159/000151371

Source DB:  PubMed          Journal:  Cells Tissues Organs        ISSN: 1422-6405            Impact factor:   2.481


  35 in total

1.  Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis.

Authors:  E F Eriksen; F Melsen; E Sod; I Barton; A Chines
Journal:  Bone       Date:  2002-11       Impact factor: 4.398

2.  Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats.

Authors:  Yongping Cao; Satoshi Mori; Tasuku Mashiba; Michael S Westmore; Linda Ma; Masahiko Sato; Tomoyuki Akiyama; Liping Shi; Satoshi Komatsubara; Kensaku Miyamoto; Hiromichi Norimatsu
Journal:  J Bone Miner Res       Date:  2002-12       Impact factor: 6.741

3.  Osteocyte necrosis in normal bone.

Authors:  D H Enlow
Journal:  J Dent Res       Date:  1966 Jan-Feb       Impact factor: 6.116

4.  Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures.

Authors:  T Mashiba; C H Turner; T Hirano; M R Forwood; D S Jacob; C C Johnston; D B Burr
Journal:  Bone       Date:  2001-09       Impact factor: 4.398

5.  Spatial distribution of Bax and Bcl-2 in osteocytes after bone fatigue: complementary roles in bone remodeling regulation?

Authors:  Olivier Verborgt; Nadine A Tatton; Robert J Majeska; Mitchell B Schaffler
Journal:  J Bone Miner Res       Date:  2002-05       Impact factor: 6.741

6.  A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases.

Authors:  J R Berenson; R A Vescio; L S Rosen; J M VonTeichert; M Woo; R Swift; A Savage; E Givant; M Hupkes; H Harvey; A Lipton
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

7.  Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.

Authors:  Pierrick Fournier; Sandrine Boissier; Stéphanie Filleur; Julien Guglielmi; Florence Cabon; Marc Colombel; Philippe Clézardin
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

8.  Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys.

Authors:  S Y Smith; R R Recker; M Hannan; R Müller; F Bauss
Journal:  Bone       Date:  2003-01       Impact factor: 4.398

9.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

10.  Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.

Authors:  Jeanette Wood; Karine Bonjean; Stephan Ruetz; Akeila Bellahcène; Laetitia Devy; Jean Michel Foidart; Vincent Castronovo; Jonathan R Green
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

View more
  22 in total

Review 1.  The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing.

Authors:  Matthew R Allen
Journal:  Odontology       Date:  2011-01-27       Impact factor: 2.634

Review 2.  Osteonecrosis of the jaw (ONJ): diagnosis and management in 2015.

Authors:  A Khan; A Morrison; A Cheung; W Hashem; J Compston
Journal:  Osteoporos Int       Date:  2015-10-22       Impact factor: 4.507

3.  OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.

Authors:  Rafael Scaf de Molon; Hiroaki Shimamoto; Olga Bezouglaia; Flavia Q Pirih; Sarah M Dry; Paul Kostenuik; Rogely W Boyce; Denise Dwyer; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2015-05-27       Impact factor: 6.741

4.  Ovariectomy stimulates and bisphosphonates inhibit intracortical remodeling in the mouse mandible.

Authors:  D J Kubek; D B Burr; M R Allen
Journal:  Orthod Craniofac Res       Date:  2010-11       Impact factor: 1.826

Review 5.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

6.  RANKL inhibitors induce osteonecrosis of the jaw in mice with periapical disease.

Authors:  Tara L Aghaloo; Simon Cheong; Olga Bezouglaia; Paul Kostenuik; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2014-04       Impact factor: 6.741

7.  Secretomes from mesenchymal stem cells participate in the regulation of osteoclastogenesis in vitro.

Authors:  Kenichi Ogata; Wataru Katagiri; Hideharu Hibi
Journal:  Clin Oral Investig       Date:  2016-10-29       Impact factor: 3.573

Review 8.  Pathologic fractures in bisphosphonate-related osteonecrosis of the jaw-review of the literature and review of our own cases.

Authors:  Sven Otto; Christoph Pautke; Sigurd Hafner; Ronny Hesse; Lea Franziska Reichardt; Gerson Mast; Michael Ehrenfeld; Carl-Peter Cornelius
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2013-05-31

9.  Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice.

Authors:  Ben Kang; Simon Cheong; Thawinee Chaichanasakul; Olga Bezouglaia; Elisa Atti; Sarah M Dry; Flavia Q Pirih; Tara L Aghaloo; Sotirios Tetradis
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

10.  Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw.

Authors:  Tomoya Soma; Ryotaro Iwasaki; Yuiko Sato; Tami Kobayashi; Satoshi Nakamura; Yosuke Kaneko; Eri Ito; Hiroyuki Okada; Hisato Watanabe; Kana Miyamoto; Morio Matsumoto; Masaya Nakamura; Seiji Asoda; Hiromasa Kawana; Taneaki Nakagawa; Takeshi Miyamoto
Journal:  J Bone Miner Metab       Date:  2020-11-17       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.